Axa S.A. Grows Position in Cencora, Inc. (NYSE:COR)

Axa S.A. lifted its position in shares of Cencora, Inc. (NYSE:COR) by 47.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 251,781 shares of the company’s stock after purchasing an additional 80,540 shares during the quarter. Axa S.A. owned about 0.13% of Cencora worth $56,726,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Zurich Insurance Group Ltd FI grew its stake in Cencora by 1.8% during the second quarter. Zurich Insurance Group Ltd FI now owns 248,931 shares of the company’s stock worth $56,084,000 after buying an additional 4,479 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Cencora by 68.8% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 34,386 shares of the company’s stock valued at $7,747,000 after acquiring an additional 14,017 shares in the last quarter. Semmax Financial Advisors Inc. boosted its position in Cencora by 11.2% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 8,165 shares of the company’s stock worth $1,934,000 after purchasing an additional 824 shares during the period. Marshall Wace LLP acquired a new stake in Cencora in the 2nd quarter valued at $1,539,000. Finally, Xponance Inc. increased its holdings in Cencora by 0.8% in the 2nd quarter. Xponance Inc. now owns 63,424 shares of the company’s stock valued at $14,289,000 after purchasing an additional 505 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at $63,323,746.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The disclosure for this sale can be found here. Insiders have sold 4,450,399 shares of company stock worth $1,070,392,799 over the last ninety days. 15.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on COR. Leerink Partners reaffirmed an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Robert W. Baird decreased their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a report on Friday, September 6th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Bank of America reaffirmed a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.67.

Cencora Trading Down 0.9 %

COR opened at $223.43 on Thursday. Cencora, Inc. has a 12-month low of $178.21 and a 12-month high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock has a market capitalization of $44.56 billion, a PE ratio of 24.45, a P/E/G ratio of 1.58 and a beta of 0.44. The firm’s fifty day moving average price is $234.93 and its 200 day moving average price is $232.89.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company posted $2.92 earnings per share. As a group, research analysts expect that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.